Change in percentage between baseline and after 6 weeks of treatment with crizotinib assessed using SUV_max (1A, N = 13), SUV_peak (1B, N = 10) and RECIST (1C, N = 13).

Change in percentage between baseline and after 6 weeks of treatment with crizotinib assessed using SUVmax (1A, N = 13), SUVpeak (1B, N = 10) and RECIST (1C, N = 13).</p

¹⁸F-FDG maximum intensity projection of patient 2 and 8 prior to (A, B) and after 6 weeks of treatment with crizotinib (C, D).

<p>Scale is from 0–15 SUV. These images illustrate the clinically dramatic decrease in ¹⁸F-FDG uptake, with both patients having a PMR according to both PERCIST criteria and the EORTC recommendations.</p

Baseline patient characteristics.

<p>Baseline patient characteristics.</p

Baseline ¹⁸F-FDG PET and CT tumor response measurements with PERCIST and EORTC criteria and progression-free survival per patient with ALK positive NSCLC.

<p>Baseline ¹⁸F-FDG PET and CT tumor response measurements with PERCIST and EORTC criteria and progression-free survival per patient with ALK positive NSCLC.</p

Patient characteristics and lesion distribution.

<p>Patient characteristics and lesion distribution.</p

Bland Altman plots.

<p><b>(A)</b> Display Bland Altman plot observer 1 and 2 volumetric method (cc). (B) Display Bland Altman plot observer 1 and R (radiologist) volumetric method (cc). (C) Display Bland Altman plot observer 2 and R volumetric method (cc). (D) Display Bland Altman plot observer 1 and 2 manual method (mm). (E) Display Bland Altman plot observer 1 and R manual method (mm). (F) Display Bland Altman plot observer 2 and R manual method (mm). Mean difference and limits of agreement are displayed as reference lines.</p

Distribution of retroperitoneal lymph nodes.

<p>RPAO: right para-aortic, LPAO: left para-aortic, CLRV: caudal left renal vein, CAV: vena cava, AOB: aortic bifurcation.</p

Measurement according to RECIST in one dimension.

<p>Long axis and short axis measurement in cm is shown in the figure.</p

Distribution of manual and volumetric lymph node measurements (mm).

<p>Distribution of manual and volumetric lymph node measurements (mm).</p

Overview intra class correlation values between observers across methods.

<p>Overview intra class correlation values between observers across methods.</p